Amylyx Pharmaceuticals (AMLX) Receivables - Net (2022 - 2025)

Amylyx Pharmaceuticals' Receivables - Net history runs 4 years deep, the most recent figure standing at $88000.0 for Q4 2025.

• On a quarterly basis, Receivables - Net fell 80.31% year-over-year to $88000.0 in Q4 2025; TTM through Dec 2025 was $88000.0, a 80.31% decrease from a year earlier, with the FY2025 full-year figure at $88000.0, down 80.31% from the prior year.
• Receivables - Net declined to $88000.0 in Q4 2025 per AMLX's latest filing, from $132000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $40.0 million in Q4 2023 and bottomed at $88000.0 in Q4 2025.
• The 4-year median for Receivables - Net is $2.9 million (2024), against an average of $11.7 million.
• Across the five-year window, Receivables - Net surged 21325.55% in 2023 and plunged 98.88% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $15.3 million in 2022, then surged by 161.66% to $40.0 million in 2023, then plunged by 98.88% to $447000.0 in 2024, then slumped by 80.31% to $88000.0 in 2025.
• Per Business Quant, the three latest AMLX Receivables - Net figures stand at $88000.0 (Q4 2025), $132000.0 (Q3 2025), and $103000.0 (Q2 2025).